J&J Opens Janssen Labs at San Diego

Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego

Novel Life Science Innovation Center to spur science by supporting early-stage life science industry

SAN DIEGO, Jan. 17, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen) today opens Janssen Labs at San Diego, a 30,000-square-foot life science innovation center, located within the company's Janssen West Coast Research Center. The innovation center provides a capital efficient, flexible lab environment for start-up companies pursuing new technologies and research platforms to advance medical care.

"A thriving biotech ecosystem is crucial for the success of the pharmaceutical industry as a whole," said Diego Miralles, M.D., site head for the West Coast Research Center. "Recent challenges in the economic environment have made it difficult for many emerging biotech companies. We believe that supporting and nurturing these companies will be good for the entire industry."

Job Post: Director, Medical Affairs, Johnson & Johnson

Johnson & Johnson companies are equal opportunity employers.

Director, Medical Affairs-1382110629

Description

Cordis, LLC, a member of Johnson & Johnson's Family of Companies is recruiting for a Director, Medical Affairs, located in Bridgewater, NJ.

Ground breaking, life changing careers that reward the power of ideas and innovation.
For more than 40 years, Cordis Corporation has pioneered less invasive treatments for vascular disease. Technological innovation and a deep understanding of the medical marketplace and the needs of patients have made Cordis the world's leading developer and manufacturer of breakthrough products for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. Today, over 7,000 Cordis employees worldwide share a strong commitment to continue the Company's groundbreaking work in the fight against vascular disease.

From a junior salesman to a CEO of Johnson & Johnson

Here's an inspirational story of a man who started working for Johnson & Johnson as a junior salesman and climbed his way to the top. 

Richard B. Sellars, a former chairman and chief executive of Johnson & Johnson passed away last week.  He was 94.

Here's a snippet from the New York Times article:

Joining the company in 1939 as a junior salesman for its new Ortho Pharmaceutical division, Mr. Sellars worked for Johnson & Johnson for 40 years. He became the company’s chairman and chief executive in 1973, the second person outside of the founding Johnson family to head the health care conglomerate.

You can read more here on the J&J website.

Pfizer Oncology: Martine J. George, M.D., M.Sc

Pfizer announced the appointment of Martine J. George, M.D., M.Sc, to Vice President of Medical Affairs for its Oncology Business Unit. Dr. George received her M.Sc in Pharmacology from Montreal University and her M.D. from Paris University. Her industry experience includes companies like J&J, Ortho Biotech, Novartis, sanofi-aventis, and more.

Because the pharmaceutical industry is really an international business, there are opportunities even in the United States for foreign medical graduates (FMGs) / international medical graduates (IMGs). In order to climb the corporate ladder, you have to have strong business skills and excellent people skills. If you're an FMG or IMG interested in non-clinical opportunities, build your social network so that you can find the right types of opportunities.

Rivaroxaban to be Reviewed by the FDA Panel on March 19

March 19 is match day for 4th year medical students. It's also the day when the FDA Panel is supposed to review the anticoagulant rivaroxaban (also known as BAY 59-7939 or Xarelto). It is an oral, direct Factor Xa inhibitor (I don't think I'll ever forget that coagulation cascade diagram that I learned in medical school). If approved, this drug could shut down all those coumadin (warfarin) clinics out there that monitor blood INR in people taking this vitamin K antagonist. Rivaroxaban would not require any blood monitoring. Plus, all those home INR tests manufacturers would need to look for something new to do.

I think everyone is wondering how the FDA will react to this new medication. If approved by the FDA, rivaroxaban will be sold in the US for short-term use as a prophylactic anticoagulant for patients undergoing knee- and hip-replacement surgeries. I'm sure the drug manufacturers will go for additional indications later on. Rivaroxaban is manufactured by Bayer and will be marketed by Ortho-McNeil Pharmaceutical which is a Johnson & Johnson group.